中国专家最新研究为晚期肺鳞癌患者带来全新更优治疗选择

Core Viewpoint - The latest research by Chinese medical experts offers a new and superior treatment option for patients with advanced squamous non-small cell lung cancer (NSCLC) through a combination of immune and anti-angiogenic therapies, specifically using the bispecific antibody Ivorisumab in conjunction with chemotherapy [1][2][4]. Group 1: Research Findings - The study led by Professor Lu Shun from Shanghai Chest Hospital explores the efficacy and safety of Ivorisumab combined with chemotherapy as a first-line treatment for advanced squamous NSCLC, marking a significant advancement in treatment strategies [1][2]. - Ivorisumab, a PD-1/VEGF bispecific immunotherapy drug developed in China, not only demonstrates anti-tumor effects but also mitigates bleeding risks associated with traditional anti-angiogenic drugs [2][3]. - The research results indicate that the median progression-free survival (PFS) for the Ivorisumab group was 11.14 months, compared to only 6.9 months for the control group receiving a different treatment [3]. Group 2: Clinical Implications - The findings represent the best historical PFS for first-line treatment of squamous NSCLC, significantly extending patient survival and achieving dual improvements in efficacy and safety [4]. - This research is expected to reshape the global landscape of cancer treatment, marking a major breakthrough in the field of tumor immunotherapy [4].